Robinson B A, Clutterbuck R D, Millar J L, McElwain T J
Br J Cancer. 1986 May;53(5):607-14. doi: 10.1038/bjc.1986.103.
Verapamil had previously been shown to increase cellular melphalan uptake and cytotoxicity in fibrosarcomas, and increased the area under the blood concentration versus time curve (AUC) for melphalan in CBA mice. Verapamil (10 mg kg-1 i.p.) had no effect on the fractional distribution of cardiac output (FDCO), measured with 86Rb-rubidium chloride, to subcutaneous fibrosarcomas. 14C-Melphalan uptake by FS13 fibrosarcomas was increased 60 min after verapamil (10 mg kg-1 i.p.), but not after lower doses which did not affect the AUC. Flunarizine (5 mg kg-1 i.p.) also had no effect on FDCO to FS13 fibrosarcomas, and tended to increase 14C-melphalan content of blood and the fibrosarcomas and to promote growth delay by melphalan. Alcohol increased FDCO to FS13 fibrosarcomas, maximally at a 1:20 dilution in saline, but had no effect on 14C-melphalan uptake or growth delay. Thus, melphalan cytotoxicity correlated with tumour melphalan uptake, and both followed changes in the AUC for melphalan but not changes in FDCO. In these murine fibrosarcomas melphalan uptake and cytotoxicity were not limited by blood flow. In subcutaneous human melanoma HX46 xenografts, verapamil had no effect on the FDCO, nor on 14C-melphalan uptake, and did not affect blood 14C-melphalan levels, suggesting absence of effects on the AUC and on cellular uptake. Alcohol did not increase the FDCO to HX46 xenografts, providing evidence for a different vascular supply.
维拉帕米先前已被证明可增加纤维肉瘤细胞对美法仑的摄取和细胞毒性,并增加CBA小鼠中美法仑的血药浓度-时间曲线下面积(AUC)。维拉帕米(10mg/kg腹腔注射)对用氯化铷86Rb测量的心脏输出量分数分布(FDCO)至皮下纤维肉瘤没有影响。维拉帕米(10mg/kg腹腔注射)60分钟后,FS13纤维肉瘤对14C-美法仑的摄取增加,但较低剂量且不影响AUC时则未增加。氟桂利嗪(5mg/kg腹腔注射)对FS13纤维肉瘤的FDCO也没有影响,并倾向于增加血液和纤维肉瘤中14C-美法仑的含量,并促进美法仑诱导的生长延迟。酒精可增加至FS13纤维肉瘤的FDCO,在盐水中以1:20稀释时最大,但对14C-美法仑的摄取或生长延迟没有影响。因此,美法仑的细胞毒性与肿瘤中美法仑的摄取相关,两者均随美法仑AUC的变化而变化,但不随FDCO的变化而变化。在这些小鼠纤维肉瘤中,美法仑的摄取和细胞毒性不受血流限制。在皮下人黑色素瘤HX46异种移植瘤中,维拉帕米对FDCO、14C-美法仑的摄取均无影响,也不影响血液中14C-美法仑水平,提示对AUC和细胞摄取均无影响。酒精不会增加至HX46异种移植瘤的FDCO,这为不同的血管供应提供了证据。